TransCode Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

TransCode Therapeutics CEO'su Philippe Calais, Oct2025 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0% doğrudan sahiptir ve bu hisselerin değeri $ 7.49 dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.4 yıl ve 4.9 yıldır.

Anahtar bilgiler

Philippe Calais

İcra Kurulu Başkanı

US$212.5k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.0001%
Yönetim ortalama görev süresi	7.4yrs
Yönetim Kurulu ortalama görev süresi	4.9yrs

Son yönetim güncellemeleri

Recent updates

TransCode Therapeutics reports Q2 results

Aug 15

TransCode files U.S. patent application for radiotherapy based cancer treatment

Jul 11

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Apr 01

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

Dec 15

CEO

Philippe Calais (66 yo)

less than a year

Görev süresi

US$212,535

Tazminat

Dr. Philippe P. Calais, Pharm. D. Ph.D. served as President, Chief Executive Officer and Director of MatriSys Bioscience, Inc. since January 13, 2024. Dr. Calais has been Executive Chairman of the Board of...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Philippe Calais	CEO & Executive Chairman of the Board	less than a year	US$212.54k	0.00011% $ 7.5
Thomas Fitzgerald	CFO, President	7.4yrs	US$956.97k	0.00022% $ 15.0
Zdravka Medarova	Co-Founder & Chief Scientific Officer	9.9yrs	Veri yok	Veri yok
Anna Moore	Co-Founder	9.9yrs	Veri yok	Veri yok
Susan Duggan	Senior Vice President of Operations	no data	Veri yok	Veri yok
Daniel Vlock	Chief Medical Officer	1.8yrs	Veri yok	Veri yok

7.4yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim: RNAZ 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Philippe Calais	CEO & Executive Chairman of the Board	7.2yrs	US$212.54k	0.00011% $ 7.5
Thomas Fitzgerald	CFO, President	7.4yrs	US$956.97k	0.00022% $ 15.0
Anna Moore	Co-Founder	9.9yrs	Veri yok	Veri yok
Elizabeth Czerepak	Independent Director	less than a year	Veri yok	Veri yok
Phillip Zamore	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Magda Marquet	Independent Director	4.9yrs	US$62.54k	0% $ 0
Keith Flaherty	Member of Advisory Board	no data	Veri yok	Veri yok
Lubomir Nechev	Member of Advisory Board	4.8yrs	Veri yok	Veri yok
Frank Slack	Member of Advisory Board	3.3yrs	Veri yok	Veri yok
Dejan Juric	Member of Advisory Board	4.3yrs	Veri yok	Veri yok
Erik Manting	Independent Director	5yrs	US$60.54k	0% $ 0

4.9yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RNAZ 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/12/26 04:38
Gün Sonu Hisse Fiyatı	2025/12/26 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

TransCode Therapeutics, Inc. 1 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Emily Bodnar	H.C. Wainwright & Co.

TransCode Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

TransCode Therapeutics, Inc., Annual General Meeting, Aug 29, 2025

TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Announces Management Changes

TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board

Recent updates

TransCode Therapeutics Presents Preliminary Data from Its Completed Phase 1a Study with Tx-MC138 in Metastatic Disease at ESMO

TransCode Therapeutics, Inc. announced that it expects to receive $25.00146 million in funding

TransCode Therapeutics, Inc., Annual General Meeting, Aug 29, 2025

TransCode Therapeutics, Inc. Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial

TransCode Therapeutics, Inc. Reports Further Progress on Phase 1A Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

TransCode Therapeutics, Inc. announced delayed annual 10-K filing

TransCode Therapeutics, Inc. Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial Withttx-Mc138

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $10.045 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split to Meet the Minimum Bid Price Requirement

TransCode Therapeutics, Inc. announced that it expects to receive $8 million in funding

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Regain Compliance with Nasdaq Bid Price Requirement

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

Transcode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, A MicroRNA-Targeted Technology

TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq

TransCode Therapeutics, Inc. Announces First Patients Treated in Phase 1 Clinical Trial with First-In-Class Lead Therapeutic Candidate

TransCode Therapeutics Receives Deficiency Letters from the Listing Qualifications Department (The “Staff”) of the Nasdaq

TransCode Therapeutics, Inc. Announces Phase 1 Clinical Trial Initiation

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Intends to File a Request for a Hearing on or before May 14, 2024, in Response to Non-Compliance with the Nasdaq Listing Rule 5550(a)(2)

TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.194863 million.

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million.

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Announces Management Changes

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with Its Lead Candidate, TTX-MC138

TransCode Therapeutics, Inc. to Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Required for Continued Listing on The Nasdaq Capital Market

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on the Nasdaq Stock Market Subject to Conditions

Transcode Therapeutics, Inc. Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Leading Therapeutic Candidate, Tx-Mc138

TransCode Therapeutics, Inc. Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate,TTX-MC138

TransCode Therapeutics, Inc. Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial

TransCode Therapeutics Provides Non Compliance Update

TransCode Therapeutics Receives Delisting Determination Letter from Nasdaq Advising Not to Accept its Compliance Plan, and Denies its Request for an Extension

TransCode Therapeutics, Inc. Announces Publication of New Data Supporting Use of TTX-MC138 for Treatment of Metastatic Breast Cancer

New major risk - Shareholder dilution

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Lead Candidate, Tx-MC138, in Glioblastoma

TransCode Therapeutics Announces 1-For-20 Reverse Stock Split to Satisfy the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

TransCode Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

Transcode Therapeutics, Inc. Announces FDA Authorization to Proceed with First-In-Human Clinical Trial

Transcode Therapeutics Announces Eind Submission to Us Fda for Planned First-In-Human Clinical Trial in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology

TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board

TransCode Therapeutics reports Q2 results

TransCode files U.S. patent application for radiotherapy based cancer treatment

Co-Founder recently bought US$55k worth of stock

TransCode Therapeutics, Inc. Acquires Option for Radiotheranostic Technology

TransCode Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

TransCode Therapeutics, Inc. Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer

CEO

Liderlik Ekibi